A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

NCT06869551 · tracked via the Priya Life Science USA tracker

Sponsor

Bristol-Myers Squibb

Phase

Phase 3

Started

2025-03-13

Last updated

2026-08-19

Condition(s) studied

Juvenile Psoriatic Arthritis

Investigational drug(s) / intervention(s)

DeucravacitinibPlacebo

Deucravacitinib: Specified dose on specified days

Placebo: Specified dose on specified days

Study summary

The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.

Eligibility

Sex

ALL

Min age

5 Years

Max age

17 Years

Healthy volunteers

Inclusion Criteria * Participants must have been diagnosed with Juvenile Psoriatic Arthritis (JPsA). * Participants must have at least three joints that are affected by arthritis. * Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems. Exclusion Criteria * Participants must not have been diagnosed with JPsA before 5 years of age. * Participants must not have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA, * Participants must not have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months. * Other protocol-defined Inclusion/Exclusion criteria apply.

Primary outcome measure(s)

Time to first flare during the withdrawal period — From week 16 up to week 42

Trial sites (47)

Facility	City	Region	Status
Local Institution - 0038	Lancaster	California	Withdrawn
Local Institution - 0020	Chicago	Illinois	Withdrawn
Local Institution - 0023	Indianapolis	Indiana	Withdrawn
Local Institution - 0059	North New Hyde Park	New York	Withdrawn
Local Institution - 0065	Cincinnati	Ohio	Withdrawn
Local Institution - 0066	Cleveland	Ohio	Withdrawn
Local Institution - 0036	Austin	Texas	Withdrawn
Centro de Oncologia Leonardo Da Vinci - ATO Terapias	Fortaleza	Ceará	Recruiting
Local Institution - 0032	Cuiabá	Mato Grosso	Withdrawn
Santa Casa de Misericordia de Belo Horizonte	Belo Horizonte	Minas Gerais	Recruiting
Hospital Pequeno Príncipe / Associação Hospitalar de Proteção à Infância	Curitiba	Paraná	Recruiting
Local Institution - 0013	Curitiba	Paraná	Withdrawn
Hospital Das Clinicas Ufpe	Recife	Pernambuco	Recruiting
Local Institution - 0033	Porto Alegre	Rio Grande do Sul	Withdrawn
LMK Serviços Médicos S/S	Porto Alegre	Rio Grande do Sul	Recruiting
PSEG- Pesquisa Clínica	Vila Clementino	São Paulo-SP	Recruiting
Local Institution - 0027	Rio de Janeiro	Brazil	Not Yet Recruiting
Santa Casa Instituto de Pesquisa	São Paulo	Brazil	Recruiting
Local Institution - 0010	São Paulo	Brazil	Withdrawn
University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD	Plovdiv	Bulgaria	Recruiting
Local Institution - 0069	Sofia	Bulgaria	Not Yet Recruiting
Local Institution - 0062	Sofia	Bulgaria	Withdrawn
Local Institution - 0074	Beijing	Beijing Municipality	Not Yet Recruiting
Local Institution - 0049	Beijing	Beijing Municipality	Not Yet Recruiting
The Children's Hospital of Chongqing Medical University	Chongqing	Chongqing Municipality	Recruiting
Guangzhou Women and Children's Medical Center	Guangzhou	Guangdong	Recruiting
Childrens Hospital of Nanjing Medical University	Nanjing	Jiangsu	Recruiting
The First Hospital of Jilin University	Changchun	Jilin	Recruiting
The Children's Hospital of Zhejiang University School of Medicine	Hangzhou	Zhejiang	Recruiting
Children's Hospital of Fudan University	Shanghai	China	Recruiting
Fakultni nemocnice Olomouc	Olomouc	Olomouc Region	Recruiting
Fakultni nemocnice v Motole	Prague	Praha 5	Recruiting
Kinderklinik des Uni-Klinikums Erlangen	Erlangen	Germany	Recruiting
Praxis Kinder- und Jugendrheumatologie Dr. Ivan Foeldvari	Hamburg	Germany	Recruiting
University of Naples Federico II	Naples	Campania	Recruiting
Azienda Ospedaliera Universitaria Meyer IRCCS	Florence	Tuscany	Recruiting
Local Institution - 0017	San Juan	Puerto Rico	Withdrawn
Spitalul Clinic de Urgenta pentru Copii Cluj-Napoca	Cluj-Napoca	Cluj	Recruiting
Local Institution - 0048	Iași	Iaşi	Withdrawn
Sc Medaudio-Optica Srl	Râmnicu Vâlcea	Vâlcea County	Recruiting

+ 7 more sites — see the full list on the official registry below.

More Bristol-Myers Squibb trials in the USA

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) Recruiting

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) Recruiting

A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT Recruiting

A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer Active, not recruiting

A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5) Recruiting

Other trials for the same condition

Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA). Recruiting

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06869551 on ClinicalTrials.gov ↗ ← All trials in the USA